// App-Quantinova.ai

: The Clinical Significance of the Glomerular Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Renal Function of Caucasian Patients with Compound Heterozygosity for Hb S and β-Thalassemia

Researchers

Presenter

  • Ioannis Papassotiriou

Principal Investigators

  • Anastasia Bartzeliotou

  • Pagona Flevari

  • Maria Dimopoulou

  • Charalambos Kapogiannis

  • Vassiliki Kappou

  • Veroniki Komninaka

  • Konstantina Repa

  • Aimilia Mantzou

  • Alexandra Margeli

  • Eleni Pergantou

  • Christos Poziopoulos

  • Ersi Voskaridou

Medical Centers

  • Department of Hematology, METROPOLITAN Hospital, Athens, Greece

  • First Department of Pediatrics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

  • Haemophilia Centre/Haemostasis and Thrombosis Unit, AGHIA SOPHIA CHILDREN'S HOSPITAL, ATHENS, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thalassemia

Biomarkers

  • Cystatin C

  • Plasminogen Activator, Urokinase

  • Growth differentiation factor 15

  • Lipocalin 2

  • Interleukin 18

  • von Willebrand factor

  • Soluble urokinase plasminogen activator receptor

Drug/Treatment

  • Interleukin

  • Lutamin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved